Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 197-203 |
| Number of pages | 7 |
| Journal | HPB |
| Volume | 20 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2018 |
Fingerprint
Cite this
A Systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases. / Partelli, S; Cirocchi, Roberto; Rancoita, PMV; Muffatti, F; Andreasi, V; Crippa, S; Tamburrino, D; Falconi, M.
In: HPB, Vol. 20, No. 3, 2018, p. 197-203.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A Systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases
AU - Partelli, S
AU - Cirocchi, Roberto
AU - Rancoita, PMV
AU - Muffatti, F
AU - Andreasi, V
AU - Crippa, S
AU - Tamburrino, D
AU - Falconi, M
PY - 2018
Y1 - 2018
N2 - Background: Role of palliative pancreatic neuroendocrine neoplasm (PanNEN) resection (pPanNEN-R) is controversial. This study was designed as a meta-analysis of studies which allow a comparison of pPanNEN-R and non-surgical management (PanNEN-nR). Methods: All published studies until 2017 allowing for the comparison of pPanNEN-R and PanNEN-nR were reviewed. Primary outcome was overall survival (OS). Secondary outcomes measures included postoperative morbidity, reoperation, readmission, length of hospital stay (LOS), and quality of life (QoL). Risk of death was compared by computing the odds-ratio (OR), while 5- and 10-year OS using weighted mean differences. Results: Seven studies were included. A total of 885 patients were included, of whom 252 (28%) underwent pPanNEN-R and 633 (72%) underwent PanNEN-nR. Overall quality of included studies was fair. The risk of death was significantly reduced in patients who underwent pPanNEN-R compared to those who underwent PanNEN-nR (OR = 0.38, 95% CI 0.23-0.65). Data on postoperative morbidity, reoperation, readmission, LOS, and QoL were not adequately reported therefore a meta-analysis for the secondary outcomes was not performed. Discussion: pPanNEN-R in patients with unresectable LM seems to be associated with a better OS compared to non-surgical management but the limitations of included studies does not allow firm conclusions. © 2017 International Hepato-Pancreato-Biliary Association Inc.
AB - Background: Role of palliative pancreatic neuroendocrine neoplasm (PanNEN) resection (pPanNEN-R) is controversial. This study was designed as a meta-analysis of studies which allow a comparison of pPanNEN-R and non-surgical management (PanNEN-nR). Methods: All published studies until 2017 allowing for the comparison of pPanNEN-R and PanNEN-nR were reviewed. Primary outcome was overall survival (OS). Secondary outcomes measures included postoperative morbidity, reoperation, readmission, length of hospital stay (LOS), and quality of life (QoL). Risk of death was compared by computing the odds-ratio (OR), while 5- and 10-year OS using weighted mean differences. Results: Seven studies were included. A total of 885 patients were included, of whom 252 (28%) underwent pPanNEN-R and 633 (72%) underwent PanNEN-nR. Overall quality of included studies was fair. The risk of death was significantly reduced in patients who underwent pPanNEN-R compared to those who underwent PanNEN-nR (OR = 0.38, 95% CI 0.23-0.65). Data on postoperative morbidity, reoperation, readmission, LOS, and QoL were not adequately reported therefore a meta-analysis for the secondary outcomes was not performed. Discussion: pPanNEN-R in patients with unresectable LM seems to be associated with a better OS compared to non-surgical management but the limitations of included studies does not allow firm conclusions. © 2017 International Hepato-Pancreato-Biliary Association Inc.
U2 - 10.1016/j.hpb.2017.10.014
DO - 10.1016/j.hpb.2017.10.014
M3 - Article
VL - 20
SP - 197
EP - 203
JO - HPB
JF - HPB
SN - 1365-182X
IS - 3
ER -